Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Core EPS Growth (% cc) by Quarter
Core EPS Growth (% cc) (%)
Novartis Core EPS Growth (% cc): 8.0% in Q3 2026, down 2.0 pts from a year earlier.
Latest, Q3 2026
8.0%
Period ended Sep 30, 2026
Change on a year earlier
-2.0 pts
10.0% in Q3 2025
History
7 quarters
Since Q1 2025
Sources
7
Documents cited below
Where the Q3 2026 figure comes from
“|| Core basic earnings per share (USD) | 2.46 | 2.25 | 9 | 8 | 6.85 | 6.94 | -1 | -3”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core EPS Growth (% cc) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 8.0% | -2.0 pts | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2026 | Jun 30, 2026 | -1.0% | -25.0 pts | Novartis Form 6-K (0001114448-26-000012) ↗ |
| Q1 2026 | Mar 31, 2026 | -15.0% | -46.0 pts | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q4 2025 | Dec 31, 2025 | 2.0% | – | Novartis Form 6-K (0001114448-26-000007) ↗ |
| Q3 2025 | Sep 30, 2025 | 10.0% | – | Novartis Form 6-K (0001114448-25-000003) ↗ |
| Q2 2025 | Jun 30, 2025 | 24.0% | – | Novartis Form 6-K (0001370368-25-000012) ↗ |
| Q1 2025 | Mar 31, 2025 | 31.0% | – | Novartis Form 6-K (0001370368-25-000010) ↗ |
Cite this data
StockData. (2026). Novartis Core EPS Growth (% cc) (%), quarterly Q1 2025–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/core-eps-yoy-cc-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.